Bivalent COVID-19 Shot Efficient for Stopping Thromboembolic Occasions

THURSDAY, Jan. 11, 2024 (HealthDay Information) — A bivalent mRNA COVID-19 vaccine after receipt of an unique monovalent COVID-19 vaccine is efficient for stopping COVID-19-related thromboembolic occasions, in keeping with analysis printed within the Jan. 11 problem of the U.S. Facilities for Illness Management and Prevention Morbidity and Mortality Weekly Report.

Amanda B. Payne, Ph.D., from the CDC in Atlanta, and colleagues estimated the incremental good thing about receipt of a bivalent mRNA COVID-19 vaccine after receipt of an unique monovalent COVID-19 vaccine. Two retrospective cohort research had been carried out amongst Medicare fee-for-service enrollees throughout Sept. 4, 2022, to March 4, 2023, to estimate the vaccine effectiveness (VE) of a bivalent mRNA COVID-19 dose for stopping thromboembolic occasions versus unique monovalent COVID-19 doses solely.

The researchers discovered that the effectiveness of a bivalent mRNA COVID-19 vaccine dose versus the unique vaccine alone in opposition to COVID-19-related thromboembolic occasions was 47 and 51 p.c amongst Medicare enrollees aged 65 years and older and amongst adults aged 18 years and older with finish stage renal illness receiving dialysis, respectively. Amongst Medicare beneficiaries who had been immunocompromised, VE was comparable: 46 and 45 p.c amongst adults aged 65 years and older and people aged 18 years and older with end-stage renal illness, respectively.

“To forestall COVID-19-related problems, together with thromboembolic occasions, adults ought to keep updated with really helpful COVID-19 vaccination,” the authors write.

Summary/Full Textual content